Minerva Neurosciences to Host Webcast Event on Schizophrenia
March 18 2019 - 8:30AM
Minerva Neurosciences to Host Webcast Event on Schizophrenia
Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
that it will host a webcast, “Schizophrenia: Disease Landscape and
Forecast,” on Thursday, March 21, 2019 beginning at 10:00
a.m. eastern time in Boston, MA.
Minerva’s Executive Chairman and Chief Executive Officer, Remy
Luthringer, Ph.D., will be joined by representatives from Decision
Resources Group, a global information and technology services
company providing proprietary data and solutions to the healthcare
industry, and Dr. Gregory Strauss, an expert key opinion
leader.
Discussions will feature the following speakers and
topics:
- Ryan Sowers, M.S. and Emma McFadden, Ph.D., Decision Resources
Group: Schizophrenia: disease landscape and
forecast
- Gregory P. Strauss, Ph.D., Assistant Professor;
Director: Clinical Affective Neuroscience Laboratory;
Director: Georgia Psychiatric Risk Evaluation
Program; Department of Psychology, University of Georgia:
The importance of negative symptoms in the
treatment of schizophrenia
- Remy Luthringer, Ph.D., Executive Chairman and Chief Executive
Officer, Minerva Neurosciences, Inc.: Roluperidone:
Targeting the leading unmet need in
schizophrenia
Institutional investors and analysts may RSVP to Mike
Biega: mbiega@soleburytrout.com. Interested parties
may access the live video webcast of this presentation by visiting
the Investors & Media section of Minerva’s website
at www.minervaneurosciences.com. A webcast replay of the
presentation will be posted on the Minerva website approximately
two hours after the event and can be accessed at:
https://www.webcaster4.com/Webcast/Page/359/29852.
Decision Resources Group is not being compensated for their
appearance and participation in this event.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a portfolio of product candidates to treat CNS
diseases. Minerva’s proprietary compounds include:
roluperidone (MIN-101), in Phase 3 clinical development for
schizophrenia; seltorexant (MIN-202 or JNJ-42847922) in Phase 2b
clinical development for insomnia and major depressive disorder
(MDD); MIN-117, in Phase 2b clinical development for MDD; and
MIN-301, in pre-clinical development for Parkinson’s disease.
Minerva’s common stock is listed on the NASDAQ Global Market under
the symbol “NERV.” For more information, please visit
www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release and webcast announced herein contains
forward-looking statements which are subject to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
as amended. Forward-looking statements are statements that
are not historical facts, reflect management’s expectations as of
the date of this press release, and involve certain risks and
uncertainties. Forward-looking statements include statements
herein with respect to the timing and scope of future clinical
trials and results of clinical trials with roluperidone,
seltorexant, MIN-117 and MIN-301; the timing and scope of future
clinical trials and results of clinical trials with these
compounds; the clinical and therapeutic potential of these
compounds; the timing and outcomes of future interactions with U.S.
and foreign regulatory bodies; our ability to successfully develop
and commercialize our therapeutic products; the sufficiency of our
current cash position to fund our operations; and management’s
ability to successfully achieve its goals. These
forward-looking statements are based on our current expectations
and may differ materially from actual results due to a variety of
factors including, without limitation, whether roluperidone,
seltorexant, MIN-117 and MIN-301 will advance further in the
clinical trials process and whether and when, if at all, they will
receive final approval from the U.S. Food and Drug Administration
or equivalent foreign regulatory agencies and for which
indications; whether any of our therapeutic products will be
successfully marketed if approved; whether any of our therapeutic
product discovery and development efforts will be successful;
management’s ability to successfully achieve its goals; our ability
to raise additional capital to fund our operations on terms
acceptable to us; and general economic conditions. These and
other potential risks and uncertainties that could cause actual
results to differ from the results predicted are more fully
detailed under the caption “Risk Factors” in our filings with the
Securities and Exchange Commission, including our Annual Report on
Form 10-K for the year ended December 31, 2018, filed with
the Securities and Exchange Commission on March 12,
2019. Copies of reports filed with the SEC are
posted on our website at www.minervaneurosciences.com. The
forward-looking statements in this press release are based on
information available to us as of the date hereof, and we disclaim
any obligation to update any forward-looking statements, except as
required by law.
Contact:
William B. BoniVP, Investor Relations/Corp.
CommunicationsMinerva Neurosciences, Inc.(617) 600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2023 to Apr 2024